CD30 antigen: Not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response

Transplant Immunology

Volumn 12, Issue 1, 2003, Pages 49-61

  Pellegrini, Patrizia ^a   Berghella, Annà Maria ^a   Contasta, Ida ^a   Adorno, Domenico ^a  

^a CNR Ist Trapianti d'Organo l'I   (Italy)

Author keywords

CD30 antigen; Costimulator molecule; Immunological markers; TH1 TH2 balance

Indexed keywords

CD30 ANTIGEN; CD30 LIGAND; CYTOKINE; GAMMA INTERFERON; HEPARIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY CD3 PLUS M81; MONOCLONAL ANTIBODY CD30; MONOCLONAL ANTIBODY CD30 LIGAND; MONOCLONAL ANTIBODY GAMMA INTERFERON; MONOCLONAL ANTIBODY INTERLEUKIN 4; MONOCLONAL ANTIBODY M44 CD30 LIGAND; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; ALLOIMMUNITY; ANTIGEN EXPRESSION; ARTICLE; BLOOD CULTURE; CELL ACTIVITY; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INHIBITION; DRUG MECHANISM; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOREGULATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SUPERNATANT; TH1 CELL; TH2 CELL; TREATMENT PLANNING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, CD30; BIOLOGICAL MARKERS; BLOOD CELLS; CELL CULTURE; CYTOKINES; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERFERON TYPE II; INTERLEUKIN-4; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; TH1 CELLS; TH2 CELLS;

EID: 0142182177     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(03)00014-5     Document Type: Article

References (46)

1. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421-427.
2. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993;73:1349-1360.
3. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 1994;76:959-962.
4. Schwab U, Stein H, Gerders J, et al. Production of a monoclonal antibody specific for Hodking and Sternberg-Reed cell of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982;299:65-67.
5. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-858.
6. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood 1995;85:3378-3404.
7. Madsen JC, Peugh WN, Wood KJ, Morris PJ. The effect of anti-L3T4 monoclonal antibody treatment on first-set rejection of murine cardiac allografts. Transplantation 1987;44:849-852.
8. Alzona M, Jack JM, Fisher RI, Ellis TM. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol 1994;153:2861-2867.
9. McDonald PP, Cassatella MA, Bald A, et al. CD30 ligation induces nuclear factor-kappa B activation in human T cell lines. Eur J Immunol 1995;25:2870-2876.
10. Ansieau S, Scheffrahn I, Mosialos G, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci USA 1996;93:14053-14058.
11. Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF)5 and TRAF2 are involved in CD30-mediated NFkB activation. J Biol Chem 1997;272:2042-2045.
12. Ellis TM, Simms PE, Slivnick DJ, Jack HM, Fisher RI. CD30 is a signal-transducing molecule that defines a subsets of human activated CD45RO+ T cells. Immunology 1993;151:2380-2389.
13. Del Prete G, De Carli M, D'Elios MM, et al. CD30-mediated signals promotes the development of human helper type 2-like T cells. J Exp Med 1995;182:1655-1661.
14. Latza U, Davis S, Wilhelm D, McKnight B, Seyfarth M, Stein H. Soluble cytokine receptor CD30 in atopic disorders: A case-control study. Clin Exp Allergy 1999;29:97-104.
15. Okumura M, Hidaka Y, Matsuzuka F, et al. CD30 expression and interleukin-4 and interferon-gamma production of intrathyroidal lymphocytes in Graves' disease. Thyroid 1999;9:333-339.
16. Iwagaki H, Hizuta A, Kohka H, et al. Circulating levels of soluble CD30 and other markers in colorectal cancer patients. J Med 1999;30:111-121.
17. Josimovic AO, Durkop H, Schwarting R, Backe E, Stein H, Diamant-Stein T. Ki-1 (CD30) antigen is released by K1-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989;19:157-162.
18. Marshall EK. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol 2000;156:1479-1484.
19. Krampera M, Vinante F, Tavecchia L, et al. Progressive polarizations towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration. Clin Exp Immunol 1999;117:291-297.
20. Vinante F, Krampera M, Morosato L, Rigo A, Romagnani S, Pizzolo G. Peripheral T lymphocyte cytokine profile (IFNgamma, IL2, IL4) and CD30 expression/release during measles infection. Haematologica 1999;84:683-689.
21. De Totero G, Reato G, Mauro F, et al. IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;104:589-599.
22. Nakamura T, Lee RK, Nam SY, et al. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFNgamma. J Immunol 1997;158:2090-2098.
23. Pinto A, Aldinucci D, Gloghini A, et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996;88:3299-3305.
24. Martinez OM, Villaneuva J, Abtahi S, Beatty PR, Esquivel CO, Krams SM. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 1998;65:1240-1247.
25. Kalinski P, Vieira PL, Schuitemaker JK, De Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001;97:3466-3469.
26. Costa GL, Sandora MR, Nakajima A, et al. Adoptive immunotherapy of experimental autoimmune encephalomyelite via T cell delivery of the IL-12 p40 subunit. J Immunol 2001;167:2379-2387.
27. Stanley CJ, Ragini F. Cytokines and lymphocytes. In: Remick DG, Friedland JS, editors. Cytokines in Health and Disease. New York: Marcel Dekker Inc, 1997. p.357-372.
28. Adams AB, Larsen CP, Pearson TC, Newell KA. The role of TNF receptor and THF superfamily molecules in organ transplantation. Am J Transpl 2002;2:12-18.
29. + T cells. J Immunol 1999;163:2358-2362.
30. Trambley J, Bingaman AW, Lin ET, et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999;104:1715-1722.
31. + T cell tolerance and linked suppression. J Immunol 1999;163:4805-4810.
32. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186(1):47-55.
33. Guo Z, Wang J, Meng L, et al. Cutting edge: Disruption of the membrane lymphotoxin receptor pathway inhibits intestinal allograft rejection. J Immunol 2001;106:4796-4800.
34. Tamada K, Shimozaki K, Chapoval AL, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000;6(3):283-289.
35. Bloemena E, Roos MT, Van Heijst JL, Vossen JM, Schellekens PT. Whole-blood lymphocyte cultures. J Immunol Methods 1989;122:161-167.
36. Berghella AM, Pellegrini P, Piancatelli D, et al. Progression mechanisms in colon cancer: Soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations. Cancer Immunol Immunother 1994;38:160-166.
37. Morel PA. Mathematical modeling of immunological reactions. Front Biosci 1998;3:338-347.
38. Farner LN, Hank JA, Sondel PM. Interleukin-2. Molecular and clinical aspects. In: Remick DG, Friedland JS, editors. Cytokines in Health and Disease. New York: Marcel Dekker Inc, 1997. p. 29-40.
39. Powrie F, Bean A, Moore KW. Interleukin-10. In: Remick DG, Friedland JS, editors. Cytokines in Health and Disease. New York: Marcel Dekker Inc, 1997, p. 143-152.
40. Chiarle R, Podda A, Prolla G, Podack ER, Thorbecke GJ, Inghirami G. CD30 over expression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 1999;163:194-205.
41. Lee SY, Park CG, Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 1996;183:669-674.
42. + T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol 1996;157:3229-3234.
43. Telford WG, Nam SY, Podack ER, Miller RA. CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol 1997;182:125-136.
44. Pelzl S, Opelz G, Wiesel M, et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002;73:3-6.
45. Susal C, Pelzl S, Dohler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002;13:1650-1656.
46. Bowen MA, Lee RK, Miragliotta G, Nam SY, Podack ER. Structural and expression of murine CD30 and its role in cytokine production. J Immunol 1996;156:442-449.